Antiphospholipid antibodies and cardiovascular thrombosis - PubMed
12 hours ago
- #Thrombotic risk
- #Cardiovascular thrombosis
- #Antiphospholipid antibodies
- Antiphospholipid antibodies (aPL) target phospholipids and phospholipid-binding proteins.
- Detection methods include serological tests for aPL against β2-glycoprotein 1, cardiolipin, and lupus anticoagulant functional assays.
- aPL can cause endothelial dysfunction or a hypercoagulable state, leading to venous or arterial thrombosis, especially with a 'second hit' like trauma or surgery.
- Thrombotic antiphospholipid syndrome is characterized by persistent lupus anticoagulant positivity or aPL seropositivity with thrombosis.
- aPL seropositivity is increasingly recognized in individuals not meeting traditional thrombotic antiphospholipid syndrome criteria.
- The review discusses aPL's role in predicting thrombotic cardiovascular events and potential management strategies.
- Key knowledge gaps in aPL research are identified for further study.